RBC Capital Markets downgraded Elevance Health from Outperform to Sector Perform. This decision stems from a weaker-than-expected 2026 outlook and concerns about lower margin targets. The firm also slashed its price target. These revisions reflect pressures from Medicaid and shifts in business mix, impacting profitability.

Elevance's initial 2026 projections anticipate margin pressure. Management lowered its operating margin target to 5.0% to 6.0%, down from the previous 6.5% to 7.0%. The change primarily reflects lower margins in Carelon Rx. Furthermore, the company anticipates a membership decline in Medicare Advantage and commercial plans.

The downgrade highlights execution risks associated with Elevance's long-term growth goals. RBC anticipates limited upside for the stock in the near term. Medicaid remains a key factor, with expected margin deficits this year. Investors will be watching for improvements in 2027 as rate actions and cost controls are implemented.

Elevance's strategic adjustments in Medicare Advantage and commercial segments are aimed at improving margins. However, these moves could impact membership numbers. RBC's assessment suggests a cautious outlook, particularly given the potential for challenges in 2027. The healthcare sector is always subject to shifting policy and market dynamics.